As the principal glucocorticoid in humans, cortisol plays a crucial role in modulating the metabolic and homeostatic process that protects against stress, shock, inflammation, etc.
As the principal glucocorticoid in humans, cortisol plays a crucial role in modulating the metabolic and homeostatic process that protects against stress, shock, inflammation, etc. [3] [4] [5] [6] [7] It is synthesized primarily in the zona fasciculata with a small contribution from the zona reticularis.
3) While cortisol is essentially secreted by the adrenal glands, cortisone is mainly produced using 11b-hydroxysteroid dehydrogenase isoenzymes, which interconvert cortisol to hormonally inactive cortisone.
3) Cortisol and cortisone are extensively metabolized to tetrahydro-reduced derivatives: tetrahydrocortisol (THF) and tetrahydrocortisone (THE), and their 5a-stereoisomer (allo-THF and allo-THE, respectively). 3, [7] [8] [9] Metabolism decreases the biological activity of hormones and increases their water solubility by converting them to hydrophilic compounds that can be excreted in urine. Unmetabolized cortisol and cortisone comprise only ca. 0.1% of the total urinary cortisol metabolites. At least 90% of the tetrahydro-derivatives of cortisol and cortisone metabolites are excreted into the urine as sulfate or glucuronide conjugates. [10] [11] [12] [13] Tetrahydro-11-deoxycortisol (THS) and its 5a-stereoisomer (allo-THS) which are tetrahydro-reduced metabolites of 11-deoxycortisol (11-DOC), a biosynthetic precursor of cortisol, are also excreted in urine as conjugated forms. 8, 10, 12) In order to obtain information regarding the related biochemistry, physiology, and pathophysiology of endocrine disorders, it is necessary to identify all the corticosteroid metabolites found in urine, and determine the exact structure of their conjugates, their concentration, and the dynamics of their formation and disposal.
At present, analytical methods for the detection of conjugated tetrahydrocorticosteroids are based on gas chromatography and mass spectrometric determination of hydrolyzed and derivatized compounds. [14] [15] [16] [17] [18] Although these methods are robust and sensitive, sample preparation in these indirect methods is time consuming, and the GC-MS sample throughput is relatively low. Thus the development or more straightforward methods based on the direct analysis of steroid conjugates without the need for a deconjugation process is of great interest. The application of liquid chromatographic separation interfaced by soft ionization techniques, such as electrospray ionization (ESI) with tandem mass spectrometry and/or ion trap mass spectrometry, offers an effective analytical tool for the direct monitoring of the urinary conjugates of tetrahydrocorticosteroids. 19, 20) Recently, we reported a highly sensitive and specific liquid chromatography/ESI-linear ion trap mass spectrometry method for the direct measurement of the glucuronide conjugates of THF, THE, THS, and their 5a-stereoisomer in human urine. 21) The authentic glucuronides had been chemically synthesized by Hosoda et al. [22] [23] [24] [25] One significant drawback of sulfate conjugate analysis, however, is still the lack of reference materials, which are essential for the development and application of analytical methods. In addition, conjugated reference standards are also needed within the field of steroid metabolism research. The objective of this study was to synthesize 18 sulfated conjugates of tetrahydrocorticosteroids as shown in Fig. 1 . The compounds selected in this study include possible and potential metabolites, some of which have already been detected in human urine. 3, 8, 10) 
Results and Discussion
For the purpose of a highly sensitive, selective, and accurate determination of the polar and hydrophilic sulfated conjugates of tetrahydrocorticosteroids, the best analytical method seemed to be the use of LC-MS/MS coupled with the available authentic reference standards. As part of our ongoing program to prepare new or scarce corticosteroid conjugates as potential metabolites that have clinical utility, we carried out the chemical synthesis of the 18 variants of the 3-and 21-monosulfate conjugates as well as the double-con- 21 -disulfates of THF, THS, and THE, and their corresponding "allo" series of 5a-stereoisomers (see Fig. 1 ).
The desired THF-3-and THF-21-sulfates (4b, 5d) and THF-3,21-disulfate (6b) were prepared from the 21-acetoxy derivative (1b) of cortisol (1a), according to the route depicted in Fig. 2 . A key intermediate in the synthesis of the sulfated THFs was 21-acetoxy-3a,11b,17a-trihydroxy-20-one (3), which was prepared from 1a in three steps. The transformation of conjugated D 4 -3-ketosteroids into the stereoisomeric 3-oxo-5b-(normal cis A/B-ring juncture) and 3-oxo-5a-steroids (allo trans A/B-ring juncture) has been improved by many groups of workers. It is now well recognized that the formation ratio of 3-oxo-5b-/3-oxo-5a-steroids is significantly influenced not only by the structures of the D 4 -3-ketosteroids but also the reducing agents that are employed. Combe et al. 26) have recommended the use of Pd/CaCO 3 as a hydrogenation catalyst for the reduction of D 4 -3-ketosteroids into their corresponding 3-oxo-5b-steroids. Hosoda et al. 22, 23) have carried out a procedure for the preparation of 21-acetoxy-11b,17a-dihydroxy-5b-pregnane-3,20-dione (2) and 21-acetoxy-17a-hydroxy-5b-pregnane-3,20-dione (8) from 1b and the 21-acetoxy derivative (7b) of 11-DOC (7a). Our exploratory experiments revealed that the catalytic hydrogenation of 1b and 7b in the presence of 5% Pd/CaCO 3 was unsatisfactory, and the reduction reaction did not proceed at all. However, by changing the catalyst to 10% Pd(OH) 2 /C, reduction of 1b and 7b proceeded smoothly to yield the desired 2 and 8, respectively. The use of Pd(OH) 2 /C was found to be much preferred over that of Pd/CaCO 3 .
Conversion of 3,20-dioxo-5b-steroid (2) to a key intermediate, 3a-hydroxy-20-oxo-5b-steroid (3), has previously been achieved by the reduction of 2 using a Raney nickel catalyst. 22) However, the reduction of 2 by zinc borohydride (Zn(BH 4 ) 2 ) 27, 28) offered an easier and more practical procedure for the preparation of 3. This less basic, mild zinc reagent, compared to common NaBH 4 , leaves the oxo group at C-20 in 2 intact at room temperature for 45 min during the reduction at C-3. In addition, Zn(BH 4 ) 2 reduction proceeds more simply and efficiently than with catalytic hydrogenation by Raney nickel. The a-configuration of the C-3 hydroxy group in 3 was characterized by a 3b-H signal appearing at 3.64-3.73 ppm as a broad multiplet with the half-band width of ca. 20 Hz in the 1 H-NMR spectrum. The 3a-hydroxy group in 3 was selectively sulfated with sulfur trioxide-triethylamine (SO 3 -TEA) complex in pyridine. The sulfation reaction proceeded cleanly and rapidly under mild experimental conditions. The resulting 3-sulfated compound (4a) was then hydrolyzed with sodium methoxide to remove the C-21 acetoxy group. To purify the crude THF-3-sulfate (4b), it was loaded onto an Oasis ® HLB cartridge for reversed-phase solid phase extraction. After the cartridge was washed with water to remove excess reagents and inorganic salts, elution with methanol yielded a homogeneous effluent, which was characterized as THF-3-sulfate (4b).
Meanwhile, compound 3 was selectively silylated at C-3 by tert-butyldimethylsilyl chloride (TBDMSCl) to obtain 21-acetoxy-3a -TBDMSO-11b ,17a -dihydroxy-5b -20-one (5a), which in turn was hydrolyzed with sodium methoxide to afford 3a-TBDMSO-11b,17a,21-trihydroxy-20-one (5b).
Treatment of 5b with SO 3 -TEA complex yielded 3a-TBDMSO-11b,17a-hydroxy-21-sulfate (5c). Subsequent desilylation at C-3 in 5c with HCl resulted in the formation of THF-21-sulfate (5d). Furthermore, alkaline hydrolysis of 3 with sodium methoxide, followed by sulfation of the resulting THF (6a) with SO 3 -TEA complex, afforded THF-3,21-disulfate (6b).
Essentially identical procedures were used to prepare the 3-and 21-monosulfates and 3,21-disulfates of THS (10b, 11d, 12b) and THE (14b, 15d, 16b), starting from 11-DOC (7a) and THE-21-acetate (13), respectively, as outlined in Figs. 3 and 4 .
The focus of our next synthetic targets was the "allo" series of the sulfate conjugates of tetrahydrocorticosteroids, which are the 5a-stereoisomers of sulfate-conjugated THF, THS, and THE, as shown in Fig. 5 . Of various methods for the reductive allomerization at C-5 of D 4 -3-ketosteroids reported previously, 24, 25, 29, 30) it seemed to us that the most feasible route, starting from the readily available 1b through the inversion of the configuration at C-5, offered a better way to obtain the 3-ethoxy-3,5-diene intermediate (17) . 24, 25) The procedures employed were (1) the etherification of 1b with triethyl orthoformate in the presence of a catalytic amount of p-toluenesulfonic acid and (2) selective reduction of the D 3,5 -bond in the resulting 17 over 10% Pd/C catalyst, yielding enol ether (18) , which after treatment with HCl gave the desired 19a. After chromatographic purification, the allomerized 3-oxo-5a compound (19a) was isolated in a fairly good yield.
A sterically bulky hydride reducing agent, potassium tri-sec-butylborohydride (K-Selectride ® ), is known to have high stereoselectivity in the reduction of oxo to the hydroxy group. 24, 25, 30, 31) For instance, 3-oxo-5b-and 3-oxo-5a-steroids are reduced to 3b-hydroxy-5b-and 3a-hydroxy-5a-isomers, respectively. 32) In fact, when 21-TBDMSO-11b,17a-dihydroxy-5a-3,20-dione (19c) was subjected to reduction with K-Selectride ® , the major isolated product was the axially 3a-hydroxylated product (20a). The a-configuration at C-3 in 20a was confirmed by the equatorial 3b-H signal appearing at 4.03-4.08 ppm as a multiplet with the half-band width of ca. 8 Hz in the 1 H-NMR spectrum. Prior to the reduction reaction of 19c, the C-21 acetoxy group in 19a was hydrolyzed with sodium methoxide, then the C-21 hydroxy group of the resulting 11b,17a,21-trihydroxy-5a-3,20-dione (19b) was protected with TBDMSCl to give 19c. Treatment of 20a with SO 3 -TEA complex, followed by desilylation of the resulting 3a-sulfooxy derivative (20b) with HCl, afforded the desired allo-THF-3-sulfate (20c).
Allo-THF-21-sulfate (21d) was prepared by the following sequence steps: (1) acetylation at C-3 in 20a, (2) desilylation at C-21 in 21a, (3) sulfation at C-21 in 21b, and then (4) alkaline hydrolysis at C-3 in 21c. Allo-THF-3,21-disulfate (20e) was similarly obtained by desilylation at C-21 in 20a and sulfation at both C-3 and C-21 in 20d. The preparation of allo-THE-21-sulfate (22d) and allo-THF-3,21-disulfate (22e) was also attained starting from 3a-acetoxy-21-TB-DMSO-17a-hydroxy-5a-11,20-dione (22a) by the essentially identical procedures described for the preparation of THF-21-sulfate (5d) and THF-3,21-disulfate (6b). Selective oxidation of the 3a-acetoxy-21-TBDMSO-11b,17a-dihydroxy-5a-20-one (21a) with pyridinium chlorochromate (PCC) under mild experimental conditions provided 22a in good isolated yield.
Based on the above findings, allo-THE-3-sulfate (23d) could be expected to be prepared from 22a in several steps. Unexpectedly, a preliminary experiment revealed that the attempted alkaline hydrolysis of the C-3 acetoxy group in 22a yields a complex mixture, probably arising from the decomposition products, from which the expected 21-TBDMSO- 3a,17a-dihydroxy-5a-11,20-dione was isolated in only poor yield after tedious chromatographic separation. However, by changing the starting material to 3a-acetoxy-17a,21-dihydroxy-5a-11,20-dione (22b), the reactions proceeded cleanly, and the desired 23d was obtained in three steps. The reactions involved are tritylation of the primary hydroxy group at C-21 in 22b with triphenylmethyl chloride (trityl chloride) and subsequent alkaline hydrolysis of the resulting 3a-acetoxy-17a-hydroxy-21-trityl-5a-11,20-dione (23a) with NaOH to afford 3a,17a-dihydroxy-21-trityl-5a-11,20-dione (23b). Sulfation at C-3 in 23b with SO 3 -TEA complex and desilylation of the resulting 17a-hydroxy-3a-sulfooxy-21-trityl ether (23c) with HCl yielded allo-THE-3-sulfate (23d). Figure 6 shows the synthetic route to allo-THS-3-sulfate (27c), allo-THS-21-sulfate (28d), and allo-THS-3,21-disulfate (27e), starting from 11-DOC-21-acetate (7b). Synthetic procedures for these compounds are essentially identical to those for the analogous THF sulfates (20c, 21d, 20e) mentioned above.
In conclusion, a series of the 18 variants of the 3-and 21-monosulfates and 3,21-disulfates of THF, THS, and THE, as well as their 5a-stereoisomers, are now available. These authentic reference standards would be useful for the highly sensitive, selective, and accurate LC-MS/MS determination of the sulfate conjugates of tetrahydrocorticosteroids present in human urine. A further detailed study on a method for the analytical and clinical application is now progressing in our laboratory, and the result will be reported at a later date. Instruments All melting points (mp) were determined on a micro hotstage apparatus and are uncorrected. 
. Chemical Synthesis. 21-Acetoxy-11b b,17a a-dihydroxy-5b b-pregnane-3,20-dione (2) A solution of cortisol 21-acetate (1b, 1.0 g) (prepared from cortisol by the usual acetic anhydride-pyridine method) in pyridine (14.5 ml) was hydrogenated overnight at room temperature in the presence of 10% Pd(OH) 2 /C catalyst (102 mg). After filtration of the catalyst on Celite, the filtrate was concentrated to dryness under reduced pressure. Recrystallization of the product from ethanol afforded 2 as colorless needles: yield, 445 mg (44 %); mp 220-223°C (lit., 22) mp 210-212°C 21-Acetoxy-3a a,11b b,17a a-trihydroxy-5b b-pregnan-20-one (3) To a freshly prepared solution of Zn(BH 4 ) 2 in Et 2 O (7 ml) 27) was added slowly a solution of 2 (700 mg) in dry tetrahydrofuran (8 ml) under N 2 gas, and the mixture was stirred at room temperature for 45 min. The resulting solution was diluted with EtOAc, washed with 5% HCl and water, dried over anhydrous Na 2 SO 4 , and evaporated to dryness. Purification of the product by column chromatography on silica gel with hexane-EtOAc (1 : 1, v/v) as an eluent and recrystallization of a homogeneous effluent from hexane-EtOAc gave 3 as colorless prisms: yield, 553 mg (79%); mp 197-200°C (lit., 22) 11b b,17a a,21-Trihydroxy-3a a-sulfooxy-5b b-pregnan-20-one Sodium Salt (THF-3-sulfate; 4b) To a solution of 3 (50 mg) in dry pyridine (0.5 ml) was added SO 3 -TEA complex (30 mg), and the mixture was stirred at room temperature for 30 min. After evaporation of the solvent under reduced pressure, the residue dissolved in a small amount of water was adjusted to pH 8 with 1 M NaOH and loaded onto an Oasis ® HLB cartridge. After being washed with water, elution with methanol gave the intermediary 21-acetoxy3a-sulfate (4a). This was hydrolyzed with sodium methoxide (36 mg) in methanol (1 ml) at room temperature for 1.5 h. After evaporation of the solvent, the residue dissolved in water was loaded onto an Oasis ® HLB cartridge and washed with water. Elution with methanol and recrystallization of a homogeneous effluent from methanol-Et 2 21-Acetoxy-3a a -tert-butyldimethylsilyloxy-11b b ,17a a -dihydroxy-5b bpregnan-20-one (5a) To a solution of 3 (90 mg) in pyridine (0.2 ml)-N,NЈ-dimethylformamide (DMF, 0.3 ml) was successively added imidazole (45 mg) and TBDMSCl (100 mg), and the mixture was stirred at room temperature for 4 h. The resulting slotuion was diluted with Et 2 O, washed with water, dried with anhydrous Na 2 SO 4 , and evaporated to dryness. Recrystallization of the product from acetone gave 5a as colorless leaflets: yield, 115 mg (ca. 100%); mp 200-204°C (lit., 22) mp 197-199°C 3a a-tert-Butyldimethylsilyloxy-11b b,17a a,21-trihydroxy-5b b-pregnan-20-one (5b) A mixture of 5a (200 mg) and sodium methoxide (50 mg) in methanol (5 ml) was stirred at room temperature for 1 h. After evaporation of the solvent, the residue was diluted with EtOAc, washed with water, dried over anhydrous Na 2 SO 4 , and evaporated to dryness. Purification of the crude product by column chromatography on silica gel with toluene-acetone (5 : 1, v/v) as an eluent and recrystallization of a homogeneous effluent from ether-hexane gave 5b as colorless plates: yield, 142 mg (77%); mp 179-181°C (lit., 22) mp 187-189°C). 3a a,11b b,17a a-Trihydroxy-21-sulfooxy-5b b-pregnan-20-one Sodium Salt (THF-21-sulfate; 5d) The compound 5b (50 mg) was treated with SO 3 -TEA complex (40 mg) at room temperature for 70 min, as described for the preparation of 4b. Evaporation of the solvent under reduced pressure afforded the intermediary 21-sulfate (5c). Without isolation of 5c, it was subjected to the desilylation at C-3 with 5% HCl (0.2 ml) in acetone (2 ml) at room temperature for 3 h. After evaporation of acetone under reduced pressure, the resulting solution was adjusted to pH 8 with 1 M NaOH and loaded onto an Oasis ® HLB cartridge. After being washed with water, the crude sulfated product was eluted with methanol. Recrystallization of the product from methanol-Et 2 O gave 5d as colorless amorphous substances: yield, 10 mg (21%); mp 164°C (dec. 3a a,11b b,17a a,21-Tetrahydroxy-5b b-pregnan-20-one (THF; 6a) The compound 3 (150 mg) was hydrolyzed with sodium methoxide (43 mg) as described for the preparation of 5b. After being processed analogously, the crude hydrolysis product was subjected to column chromatography on silica gel with toluene-acetone (3 : 1, v/v) as an eluent. Recrystallization of a homogeneous effluent from acetone gave 6a as colorless needles: yield, 110 mg (82%); mp 215-217°C (lit., 29) mp 202-204°C). 11b b,17a a-Dihydroxy-3a a,21-disulfooxy-5b b-pregnan-20-one Disodium Salt (THF-3,21-disulfate; 6b) The compound 6a (50 mg) was treated with SO 3 -TEA complex (50 mg) at room temperature for 1 h, followed by 1 M NaOH, as described for the preparation of 4b. After passing through an Oasis ® HLB cartridge and being washed with water, the desired sulfate was eluted with methanol. Evaporation of the solvent and recrystallization of the product from methanol afforded 6b as colorless amorphous substances: yield, 61 mg (78%); mp 139-141°C. 21-Acetoxy-3a a,17a a-dihydroxy-5b b-pregnan-20-one (9) 11-Deoxycortisol 21-acetate (7b, 500 mg) (prepared from 11-DOC (7a) by the usual acetic anhydride-pyridine method) in pyridine (22 ml) was catalytically hy-drogenated in the presence of 10% Pd(OH) 2 /C (50 mg) at room temperature overnight. After filtration of the catalyst on Celite, the filtrate was concentrated to dryness under reduced pressure, yielding the intermediary 3-oxo-5b derivative (8) . Without purification of 8, it was reduced with Zn(BH 4 ) 2 /Et 2 O solution (1.25 ml) at room temperature for 3 h and processed as described for the preparation of 3. Purification of the crude product by column chromatography on silica gel with toluene-acetone (3 : 1, v/v) as an eluent and recrystallization of a homogeneous effluent from EtOAc gave 9 as colorless needles: yield, 196 mg (39%); mp 222-225°C (lit., mp 229-232°C 23) ; 221-224°C 33) ). 1 17a a,21-Dihydroxy-3a a-sulfooxy-5b b-pregnan-20-one Sodium Salt (THS-3-sulfate; 10b) The compound 9 (50 mg) was subjected to the sulfation with SO 3 -TEA complex (30 mg) at 45°C for 4 h, as described for the preparation of 4a. After evaporation of the solvent under reduced pressure, the residue dissolved in water was loaded onto an Oasis ® HLB cartridge. After being washed with water, the desired sulfate (10a) was eluted with methanol. Subsequent hydrolysis of the condensed methanolic solution (ca. 1 ml) was attained with sodium methoxide (10 mg) at room temperature for 1 h. The solvent was evaporated and the residue dissolved in water was loaded onto an Oasis ® HLB cartridge. After being washed with water, elution with methanol afforded 10b which was recrystallized from methanol-Et 2 O as colorless amorphous substances: yield, 56 mg (97%); mp 196°C (dec.). 21-Acetoxy-3a a-tert-butyldimethylsilyloxy-17a a-hydroxy-5b b-pregnan-20-one (11a) The compound 9 (100 mg) was treated with TBDMSCl (90 mg) overnight at room temperature, as described for the preparation of 5a. After being processed analogously, the product was recrystallized from ethanol to give 11a as colorless leaflets: yield, 129 mg (ca. 100%); mp 191-193°C (lit., 23) mp 188-189°C 3a a-tert-Butyldimethylsilyloxy-17a a,21-dihydroxy-5b b-pregnan-20-one (11b) The compound 11a (50 mg) in methanol (3 ml)-tetrahydrofuran (0.5 ml) was treated with sodium methoxide (8 mg) at room temperature for 30 min, as described for the preparation of 5b. After being processed analogously, the product was recrystallized from Et 2 O-hexane to give 11b as colorless needles: yield, 45 mg (ca. 100%); mp 184-186°C (lit., 23) mp 187-189°C). 3a a,17a a-Dihydroxy-21-sulfooxy-5b b-pregnan-20-one Sodium Salt (THS-21-sulfate; 11d) The compound 11b (30 mg) was treated with SO 3 -TEA complex (50 mg) at 50°C for 26 h, as described for the preparation of 5d. After being processed analogously, the resulting 21-sulfate (11c) was subjected to the desilylation at C-3 with 5% HCl (0.1 ml) in acetone (1 ml) at room temperature for 15 min. The resulting solution was adjusted to pH 8 with 2.5 M NaOH and poured onto an Oasis ® HLB cartridge. After being washed with water, the product eluted with methanol was subjected to column chromatography on silica gel. Elution with CHCl 3 -methanol (6 : 1, v/v) yielded 11d as colorless amorphous substances, 21 mg (72%); mp 180°C (dec. 3a a,17a a,21-Trihydroxy-5b b-pregnan-20-one (THS; 12a) The compound 9 (60 mg) was hydrolyzed with sodium methoxide (21 mg) at room temperature for 1.5 h, as described for the preparation of 5b. After being processed analogously, the crude product was subjected to column chromatography on silica gel with toluene-acetone (3 : 1, v/v) as an eluent. Recrystallization of a homogeneous effluent from methanol gave 12a as colorless needles: yield, 40 mg (75%); mp 197-199°C (lit., 34) mp 222-230°C 17a a-Hydroxy-3a a,21-disulfooxy-5b b-pregnan-20-one Disodium Salt (THS-3,21-disulfate; 12b) The compound 12a (21 mg) was treated with SO 3 -TEA complex (20 mg) overnight at 40°C, followed by 1 M NaOH, as described for the preparation of 4b. After being loaded onto an Oasis ® HLB cartridge and washed with water, the desired THS-3,21-disulfate (12b) was eluted with methanol. This compound was recrystallized from methanol as colorless amorphous substances: yield, 7.3 mg (22%); mp 184°C (dec. 17a a,21-Dihydroxy-3a a-sulfooxy-5b b-pregnane-11,20-dione Sodium Salt (THE-3-sulfate; 14b) A mixture of THE-21-acetate (13, 50 mg) and SO 3 -TEA complex (50 mg) in pyridine (1 ml) was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was extracted with EtOAc. The combined extract was washed with water, dried over anhydrous Na 2 SO 4 , and evaporated to give a first crop of the intermediary 3-sulfate (14a). The aqueous layer was passed through Amberlite XAD-2 resin (10 g) and washed with water. Elution with methanol gave a second crop of 14a: total yield, 35 mg (58.5%). Without further purification, it was hydrolyzed with sodium methoxide (6 mg) in methanol (6 ml) at room temperature for 2 h, as described for the preparation of 5b. After evaporation of the solvent, the reaction product dissolved in water was passed through a reversed-phase column on Cosmosil 140C 18 -OPN (10 g) and washed with water. Elution with methanol afforded the crude product, which in turn was chromatographed on silica gel with CHCl 3 -methanol (3 : 1, v/v) as an eluent. Recrystallization of a homogeneous effluent from methanol-Et 2 O gave 14b as colorless amorphous substances: yield, 26 mg (45%); mp 177°C (dec.). 
21-Acetoxy-3a
a-tert-butyldimethylsilyloxy-17a a-hydroxy-5b b-pregnane-11,20-dione (15a) THE-21-acetate (13, 100 mg) was treated with TBDMSCl (66 mg) at room temperature for 4 h, as described for the preparation of 5a. After being processed analogously, the product was recrystallized from methanol to give 15a as colorless leaflets: yield, 128 mg (ca. 100%); mp 218-221°C (lit., 22) mp 214-216°C 3a a-tert-Butyldimethylsilyloxy-17a a,21-dihydroxy-5b b-pregnane-11,20-dione (15b) The compound 15a (30 mg) was hydrolyzed with sodium methoxide (5 mg) at room temperature for 50 min, as described for the preparation of 5b. After being processed analogously, the crude product was chromatographed on silica gel with hexane-EtOAc (2 : 1, v/v) as an eluent. Recrystallization of a homogeneous effluent from acetone gave 15b as colorless leaflets: yield, 22 mg (80%); mp 209-211°C (lit., 22) mp 208-210°C). 3a a,17a a-Dihydroxy-21-sulfooxy-5b b-pregnane-11,20-dione Sodium Salt (THE-21-sulfate; 15d) The compound 15b (25 mg) was treated with SO 3 -TEA complex (25 mg) at room temperature overnight, as described for the preparation of 4b. After evaporation of the solvent under reduced pressure, the resulting 21-sulfate (15c) dissolved in acetone (5 ml)-methanol (0.5 ml) was treated with 5% HCl (0.5 ml) at room temperature for 10 min. The mixture was adjusted to pH 8 with 5% NaHCO 3 , poured onto a column of Cosmosil (5 g), and washed with water. Elution with methanol gave the crude desilylated product, which in turn was chromatographed on silica gel with CHCl 3 -methanol (2 : 1, v/v) as an eluent. Recrystallization of a homogeneous effluent from methanol-Et 2 O gave 15d as colorless amorphous substances: yield, 20 mg (82%); mp 187°C (dec. 17a a-Hydroxy-3a a,21-disulfooxy-5b b-pregnane-11,20-dione Disodium Salt (THE-3,21-disulfate; 16b) THE (16a, 38 mg) was treated with SO 3 -TEA complex (30 mg) at 50°C overnight, followed by 1 M NaOH, as described for the preparation of 4b. The reaction mixture was passed through a column of Cosmosil (10 g) and washed with water. Elution with methanol gave the crude product, which was then chromatographed on silica gel with CHCl 3 -methanol (2 : 1, v/v) as an eluent to give 16b as colorless amorphous substances: yield, 43 mg (73%); mp 167°C (dec. 21-Acetoxy-11b b,17a a-dihydroxy-5a a-pregnane-3,20-dione (19a) To a stirred solution of cortisol 21-acetate (1b, 2.0 g) in tetrahydrofuran (70 ml)-ethanol (5 ml) was added triethyl orthoformate (7 ml) and p-toluenesulfonic acid (75 mg), and the mixture was stirred at room temperature for 2 h. After addition of pyridine (2 ml), the mixture was diluted with EtOAc. The organic layer was washed with 5% NaHCO 3 and saturated brine, dried over anhydrous Na 2 SO 4 , and evaporated to dryness. Purification of the crude product by column chromatography on silica gel with hexane-EtOAc (7 : 3, v/v) as an eluent gave the intermediary 3-ethoxy-3,5-diene (17) . This was dissolved in EtOAc-ethanol (12 ml; 1 : 1, v/v) and the solution was catalytically hydrogenated on 10% Pd/C (30 mg) overnight at room temperature. After addition of EtOAc (50 ml) followed by removal of the catalyst by filtration on Celite, the filtrate was acidified with 7.3% HCl. The organic layer was washed with 5% NaHCO 3 and saturated brine, dried over anhydrous Na 2 SO 4 , and evaporated to dryness. Purification of the product by column chromatography on silica gel with hexane-EtOAc (3 : 2, v/v) as an eluent and recrystallization of a homogeneous effluent from acetone gave 19a as colorless prisms: yield, 497 mg (25%); mp 195-197°C (lit., 29) mp 220-224°C 11b b,17a a,21-Trihydroxy-5a a-pregnane-3,20-dione (19b) The compound 19a (205 mg) was hydrolyzed with sodium methoxide (35 mg) as described for the preparation of 5b. Recrystallization of the crude product from acetone gave 19b as colorless amorphous substances: yield, 164 mg (89%); mp 229-231°C (lit., 25) mp 231-235°C). 21-tert-Butyldimethylsilyloxy-3a a,11b b,17a a-trihydroxy-5a a-pregnan-20-one (20a) To a stirred solution of 19c (497 mg) in tetrahydrofuran (3.5 ml) at Ϫ78°C was added slowly a 1 M solution of K-Selectride ® in tetrahydrofuran (1.5 ml), and the mixture was further stirred at Ϫ78°C for 1.2 h. After gradual addition of 30% H 2 O 2 (1.5 ml), the resulting solution was extracted with EtOAc. The combined extract was washed with saturated brine, dried over anhydrous Na 2 SO 4 , and evaporated. Purification of the product by column chromatography on silica gel with hexane-EtOAc (2 : 1, v/v) as an eluent and recrystallization of a homogeneous effluent from acetone gave 20a as colorless prisms: yield, 450 mg (90%). mp 173-176°C. 11b b,17a a,21-Trihydroxy-3a a-sulfooxy-5a a-pregnan-20-one Sodium Salt (Allo-THF-3-sulfate; 20c) The compound 20a (60 mg), treated with SO 3 -TEA complex (30 mg) at room temperature for 2 h and processed as described for the preparation of 5d, yielded the crude 3a-sulfate (20b). Without isolation of 20b, it was subjected to the desilylation at C-21 with 5% HCl (0.2 ml) at room temperature for 1.5 h. The resulting solution was adjusted to pH 8 with 2.5 M NaOH and extracted with EtOAc. The organic layer was dried over anhydrous Na 2 SO 4 and evaporated to give a first crop of the reaction product. Meanwhile, the aqueous layer was passed through an Oasis ® HLB cartridge, washed with water, and elution with methanol afforded a second crop. After evaporation of the solvent of the combined extract, the residue was subjected to column chromatography on silica gel. Elution with CHCl 3 -methanol (3 : 1, v/v) afforded a homogeneous fraction. After evaporation of the solvent, the residue was recrystallized from methanol-Et 2 O to give 20c as colorless amorphous substances: yield, 55 mg (94%); mp 143°C (dec.). 38 (1H, m, 11a-H), 4.59-4.64 (1H, m, 3b-H 3a a,11b b,17a a,21-Tetrahydroxy-5a a-pregnan-20-one (Allo-THF; 20d) A mixture of the compound 20a (45 mg) and 5% HCl (2 ml) in acetone (0.5 ml) was stirred at room temperature for 10 min. The desilylation product was extracted with EtOAc, and the combined extract was washed with water, dried over anhydrous Na 2 SO 4 . After evaporation of the solvent, the product was recrystallized from methanol to give 20d as colorless needles: yield, 33 mg (96%); mp 252-258°C (lit., 29) mp 248-256°C). 1H, m, 11a-H). 11b b,17a a-Dihydroxy-3a a,21-disulfooxy-5a a-pregnan-20-one Disodium Salt (Allo-THF-3,21-disulfate; 20e) The compound 20d (24 mg) was treated with SO 3 -TEA complex (58 mg) at room temperature for 2 h, followed by 1 M NaOH, as described for the preparation of 4b. After loading onto an Oasis ® HLB cartridge and being washed with water, the crude product was eluted with methanol. Chromatography of the product on a column of silica gel and elution with CHCl 3 -methanol (2 : 1, v/v) afforded 20e as colorless amorphous substances which was recrystallized from methanol-Et 2 O: yield, 38 mg (ca. 100%); mp 142-143°C. : 262.0693; Found, m/z: 262.0683. 3a a -Acetoxy-21-tert-butyldimethylsilyloxy-11b b ,17a a -dihydroxy-5a apregnan-20-one (21a) A solution of 20a (404 mg) in pyridine-acetic anhydride (3 ml; 2 : 1, v/v) was stirred overnight at room temperature. After extraction of the acetylation product with EtOAc, the combined extract was washed with 5% NaHCO 3 and water, dried over anhydrous Na 2 SO 4 , and evaporated to give 21a which was recrystallized from Et 2 O-hexane as colorless amorphous substances: yield, 418 mg (91%); mp, 163-164°C. 3a a-Acetoxy-11b b,17a a,21-trihydroxy-5a a-pregnan-20-one (21b) The compond 21a (90 mg), treated with 5% HCl (0.5 ml) at room temperature for 10 min and processed as described for the preparation of 20d, yielded the desilylation product. Recrystallization from EtOAc gave 21b as colorless needles: yield, 64 mg (91%); mp 227-229°C (lit., 25) mp 228-230°C). 3a a,11b b,17a a-Trihydroxy-21-sulfooxy-5a a-pregnan-20-one Sodium Salt (Allo-THF-21-sulfate; 21d) The compound 21b (50 mg) was treated with SO 3 -TEA complex (60 mg) at room temperature for 3 h, followed by 1 M NaOH, as described for the preparation of 4b. After being processed analogously, the resulting 21-sulfate (21c) dissolved in methanol (1 ml) was hydrolyzed with 5 M NaOH (0.3 ml) at room temperature for 20 min. The solvent was evaporated under reduced pressure and the residue dissolved in water was applied onto an Oasis ® HLB cartridge. After being washed with water, the crude product was eluted with methanol. Chromatography of the product on a column of silica gel and elution with CHCl 3 -methanol (4 : 1, v/v) afforded 21d as colorless amorphous substances which was recrystallized from methanol-Et 2 O: yield, 19 mg (33%); mp 176°C. . 3a a-Acetoxy-21-tert-butyldimethylsilyloxy-17a a-hydroxy-5a a-pregnane-11,20-dione (22a) To a solution of 21a (372 mg) in CH 2 Cl 2 (4 ml) was added Celite (500 mg), sodium acetate (19 mg) and PCC (230 mg), and the mixture was stirred at room temperature for 1.5 h. The mixture was diluted with Et 2 O and filtered on silica gel. After evaporation of the solvent in the filtrate, the residue was subjected to column chromatography on silica gel with hexane-EtOAc (5 : 1, v/v) as an eluent. Recrystallization of a homogeneous effluent from acetone-hexane gave 22a as colorless amorphous substances: yield, 283 mg (76%); mp 185-188°C. 3a a-Acetoxy-17a a,21-dihydroxy-5a a-pregnane-11,20-dione (22b) The compound 22a (60 mg), treated with 5% HCl (0.5 ml) and processed as described for the preparation of 20d, yielded the crude desilylation product. Recrystallization from acetone-hexane gave 22b as colorless needles:
yield, 45 mg (96%); mp 187-190°C (lit., 25) mp 187-190°C 3a a,17a a-Dihydroxy-21-sulfooxy-5a a-pregnane-11,20-dione Sodium Salt (Allo-THE-21-sulfate; 22d) The compound 22b (35 mg), subjected to the sulfation (at room temperature for 1.5 h) with SO 3 -TEA complex (60 mg), followed by 1 M NaOH, and processed as described for the preparation of 4b, gave the intermediary 3a-acetoxy-21-sulfate (22c). Without isolation of 22c, it was hydrolyzed with 2.5 M NaOH (0.8 ml) in methanol (2 ml) at room temperature for 1 h and then the solution was adjusted to pH 8 with 5% HCl. After being loaded onto an Oasis ® HLB cartridge and washed with water, the crude hydrolysis product was eluted with methanol. Chromatography of the product on a column of silica gel and elution with CHCl 3 -methanol (3 : 1, v/v) afforded the desired allo-THE-21-sulfate (22d) which recrystallized from methanol-Et 2 O as colorless powders: yield, 47 mg (92%); mp 169°C (dec. 25 mg) , subjected to the sulfation (at room temperature for 20 h) with SO 3 -TEA complex (80 mg), followed by 1 M NaOH, and processed as described for the preparation of 4b, gave the crude product. Chromatography of the product on a column of silica gel and elution with CHCl 3 -methanol (2 : 1, v/v) afforded allo-THE-3,21-disulfate (22e) which recrystallized from acetone-methanol-Et 2 O as colorless amorphous substances: yield, 30 mg (99%); mp 145°C (dec. : 261.0615; Found, m/z: 261.0600. 3a a-Acetoxy-17a a-hydroxy-21-trityloxy-5a a-pregnane-11,20-dione (23a) A mixture of 22b (113 mg) and trityl chloride (254 mg) in pyridine (0.5 ml) was stirred at 60°C for 3 h. After extraction of the reaction product with Et 2 O, the combined extract was washed with water, dried over anhydrous Na 2 SO 4 , and evaporated. The oily residue was subjected to column chromatography on silica gel. Elution with hexane-EtOAc (2 : 1, v/v) gave a homogenous yellow oil which was characterized as the 21- 3a a,17a a-Dihydroxy-21-trityloxy-5a a-pregnane-11,20-dione (23b) To a solution of 23a (30 mg) in methanol-tetrahydrofuran (0.6 ml; 1 : 1, v/v) was added 0.75 M NaOH (0.3 ml), and the mixture was stirred at room temperature for 6 h. The resulting solution was neutralized with 5% HCl and extracted with EtOAc. The combined extract was washed with water, dried over anhydrous Na 2 SO 4 , and evaporated. Chromatography of the residue on a column of silica gel and elution with hexane-EtOAc (1 : 1, v/v) afforded 23b as colorless amorphous substances: yield, 2.4 mg (43%); mp 145°C. 1 17a a,21-Dihydroxy-3a a-sulfooxy-5a a-pregnane-11,20-dione Sodium Salt (Allo-THE-3-sulfate; 23d) The compound 23b (8 mg) was subjected to the sulfation (at room temperature for 4 h) with SO 3 -TEA complex (18 mg) as described for the preparation of 4b. After evaporation of the solvent under reduced pressure, the crude product, 3a-sulfooxy-21-trityl ether 23c, was treated with ethanol (0.9 ml) containing conc. HCl (0.05 ml) at room temperature for 2 h, and then the solution was adjusted to pH 8 with 0.75 M NaOH. After evaporation of the solvent, the residue was diluted with EtOAc. The aqueous layer was loaded onto an Oasis ® HLB cartridge and washed with water. The desired allo-THE-3-sulfate (23d) was eluted with methanol and recrystallized from methanol-Et 2 21-Acetoxy-17a a-hydroxy-5a a-pregnane-3,20-dione (26a) To a solution of the 11-DOC-21-acetate (7b, 5.47 g) in 1,4-dioxane (110 ml) was added triethyl orthoformate (6 ml) and conc. H 2 SO 4 (23 ml) in ethanol (4 ml), and the mixture was stirred at room temperature for 1 h. Pyridine (5 ml) was added to the mixture and the reaction product was extracted with EtOAc. The combined extract was washed with 5% NaHCO 3 and saturated brine, dried over anhydrous Na 2 SO 4 , and evaporated to dryness. The residue was chromatographed on a column of silica gel. Elution with EtOAc-hexane (1 : 2, v/v) afforded the intermediary 3-ethoxy-3,5-diene (24) . This compound 24 dissolved in EtOAc (100 ml) and ethanol (100 ml) was catalytically hydrogenated over 10% Pd/C (98 mg) at room temperature for 1 h. After filtration of the catalyst on Celite, the filtrate was acidified with 12% HCl. The precipitate was filtered off to give a first fraction. The mother liquor was extracted with EtOAc, and the combined extract was washed with 5% NaHCO 3 and saturated brine, dried over anhydrous Na 2 SO 4 , and evaporated to give a second fraction. Recrystallization of the combined fraction from EtOAc gave the title compound 26a as colorless amorphous substances: yield, 3.11 g (57%); mp 246-248°C (lit., 24) mp 251-252°C 21-tert-Butyldimethylsilyloxy-17a a-hydroxy-5a a-pregnane-3,20-dione (26c) A solution of the compound 26a (501 mg) in 1,4-dioxane (60 ml) was hydrolyzed with 1% methanolic NaOH (3 ml) at room temperature for 1 h. The hydrolysis product was extracted with EtOAc, and the combined extract was washed with saturated brine, dried over anhydrous Na 2 SO 4 , and evaporated. The residue was recrystallized from methanol to give the 17a,21-dihydroxy-3,20-dioxo intermediate (26b), which was treated with TBDMSCl (586 mg) at room temperature for 1.5 h and processed as described for the preparation of 5a, yielded the silylation product. Recrystallization from methanol afforded the title compound 26c as colorless leaflets: yield, 501 mg (91%); mp 190-192°C (lit., 24) mp 191-192°C 21-tert-Butyldimethylsilyloxy-3a a,17a a-dihydroxy-5a a-pregnan-20-one (27a) The compound 26c (320 mg) was reduced with 1 M K-Selectride ® in tetrahydrofuran (1.3 ml) at Ϫ80°C for 30 min and processed as described for the preparation of 20a. The crude product was recrystallized from methanol to give 27a as colorless leaflets: yield, 285 mg (89%); mp 171-172°C (lit., 24) mp 175-177°C). 17a a,21-Dihydroxy-3a a-sulfooxy-5a a-pregnan-20-one Sodium Salt (Allo-THS-3-sulfate; 27c) The compound 27a (182 mg) was treated with SO 3 -TEA (253 mg) at room temperature for 3.5 h, as described for the preparation of 4b. After removal of pyridine by decantation of the mixture diluted with petroleum ether, the precipitated solids (21-TBDMSO-17a-hydroxy3a-sulfooxy-5a-20-one intermediate, 27b) were filtered off. To the crude 27b dissolved in a small amount of methanol was added 10% HCl (0.5 ml), and the mixture was left standing at room temperature for 30 min. The resulting solution was loaded onto a Sep-Pack ® tC 18 cartridge. Elution with methanol-water (3 : 7, v/v) gave a homogenous fraction which was then adjusted to pH 8 with 10% methanolic NaOH. The resulting solution was passed through a Sep-Pak ® tC 18 cartridge and washed with 5% aqueous methanol. Elution with 25% methanol gave 27c which recrystallized from methanol-EtOAc as colorless amorphous substances: yield, 33 mg (28%); mp 141-144°C. 3a a,17a a,21-Trihydroxy-5a a-pregnan-20-one (Allo-THS; 27d) The compound 27a (285 mg), treated with 10% HCl (50 ml) at room temperature for 30 min and processed as described for the preparation of 20d, yielded the desilylation product. The crude residue was dissolved in water was loaded onto a Sep-Pak ® tC 18 cartridge and elution with 80% methanol afforded 27d which recrystallized from methanol as colorless amorphous substances: yield, 215 mg (ca. 100%); mp 188-189°C (lit., mp 225-226°C 24) ; mp 203-213°C 36) ). 1 17a a-Hydroxy-3a a,21-disulfooxy-5a a-pregnan-20-one Disodium Salt (Allo-THS-3,21-disulfate; 27e) The compound 27d (35 mg) was treated with SO 3 -TEA (94 mg) at room temperature for 4 h, followed by 1% methanolic NaOH, as described for the preparation of 27c. After being loaded onto a Sep-pak ® tC 18 cartridge and washed with 5% aqueous methanol, the desired allo-THS-3,21-disulfate (27e) was eluted with 20% methanol. This compound was recrystallized from methanol as colorless leaflets: yield, 25 mg (45%); mp 148-151°C. : 254.0719; Found, m/z: 254.0710. 3a a-Acetoxy-21-tert-butyldimethylsilyloxy-17a a-hydroxy-5a a-pregnan-20-one (28a) The compound 27a (235 mg), treated with acetic anhydride-pyridine at room temperature overnight and processed as described for the preparation of 21a, yielded the crude acetylation product. Recrystallization from methanol-water gave the title compound 28a as colorless needles: yield, 239 mg (93%); mp 172-175°C (lit., 24) mp 179-180°C 1H, m, 3b-H) .
3a a,17a a-Dihydroxy-21-sulfooxy-5a a-pregnan-20-one Sodium Salt (Allo-THS-21-sulfate, 28d) The compound 28a (53 mg), treated with 10% HCl (8 ml) at room temperature for 1 h and processed as described for the preparation of 20d, yielded the desilylation product (28b). Without purification, it was treated with SO 3 -TEA (30 mg) at room temperature overnight, as described for the preparation of 4b, afforded the intermediary 21-sulfate (28c), which was then hydrolyzed with 10% methanolic NaOH (1 ml) overnight at 50°C. The resulting solution was diluted with water and adjusted to pH 8 with 10% HCl. After being loaded onto a Sep-pak ® tC 18 cartridge and washed with 5% aqueous methanol, the desired allo-THS-21-sulfate (28d) was eluted with 40% methanol. This compound was recrystallized from methanol as colorless amorphous substances: yield, 17 mg (51%); mp 201-203°C. 1 C-NMR chemical shifts of the eighteen 3-and 21-monosulfates and their double-conjugates of 3,21-disulfates in the 5a-and 5b-series, assigned on the basis of the parent non-sulfated corticoid analogs, 37) are compiled in Table 1 .
